三个皮匠报告—— 严选型全行业研究报告分享下载平台,您的专属行业智库!
欢迎来到三个皮匠报告!
登录
帮助中心
首页
最新
研搜
BETA
合集
英文
会议
数据
财报库
政策库
自研报告
入驻
您的当前位置:
首页
>
行业数据
>
CELESTIAL-301临床:全球唯一旨在证明相比目前固定疗程标准疗法具有PFS
CELESTIAL-301临床:全球唯一旨在证明相比目前固定疗程标准疗法具有PFS
行业数据
下载Excel
下载图片
原图定位
图片属性
图片格式:PNG
图片大小:368KB
图片尺寸:1811*734
同报告图片
/
4
fCDliIblsYLlm6DntKAgfCBB57uEIHwgQue7hCB8CnwtLS0tLS0tLS0tLXwtLS0tLXwtLS0tLXwKfCDlubTpvoQoPDY15bKB5a+55q+U4omlNjXlsoEpIHwgICAgIHwgICAgIHwKfCBJR0hWKOeqgeWPmOWvueavlOacqueqgeWPmCkgfCAgICAgfCAgICAgfAp8IOaYr+WQpuS8tOaciTE3cOe8uuWksS9UUDUz56qB5Y+YIHwgICAgIHwgICAgIHwKCui1hOaWmeadpea6kO+8muWFrOWPuOa8lOekuuadkOaWme+8jOWbvemHkeivgeWIuOeglOeptuaJgA==
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
fCDlgqzljJbliYIgICAgICAgfCDml7bpl7QgICAgICAgfAp8LS0tLS0tLS0tLS0tLS18LS0tLS0tLS0tLS0tfAp8IENESzTmipHliLbliYIgICB8IDIwMjVIMSAgICAgfAp8ICAgICAgICAgICAgICB8IDIwMjVIMiAgICAgfAp8IEI3LUg0IEFEQyAgICB8IDIwMjVIMSAgICAgfAp8ICAgICAgICAgICAgICB8IDIwMjYgICAgICAgfAp8ICAgICAgICAgICAgICB8IDIwMjVIMiAgICAgfAp8ICAgICAgICAgICAgICB8IDIwMjVIMiAgICAgfAp8ICAgICAgICAgICAgICB8IDIwMjVIMiAgICAgfAp8IEI3LUgzIEFEQyAgICB8IDIwMjVIMiAgICAgfAp8ICAgICAgICAgICAgICB8IDIwMjVIMiAgICAgfAp8ICAgICAgICAgICAgICB8IDIwMjVIMiAgICAgfAp8ICAgICAgICAgICAgICB8IDIwMjVIMiAgICAgfAp8IFBSTVQ1K01BVDJBICB8IDIwMjYgICAgICAgfAp8ICAgICAgICAgICAgICB8IDIwMjYgICAgICAgfAoK6LWE5paZ5p2l5rqQ77ya5YWs5Y+45ryU56S65p2Q5paZ77yM5Zu96YeR6K+B5Yi456CU56m25omA
fCDntKLmiZjlhYvmi4kgIHwgIFIvUiBNQ0wgMiB8IDIwMjVIMiB8CnwtLS0tLS0tLS0tfC0tLS0tLS0tLS0tLS18LS0tLS0tLS0tfAp8IEJUSyBDREFDIHwgMUwgRVNDQyAgICAgfCAyMDI1SDEgIHwKfCDmm7/pm7fliKnnj6DljZXmipcgfCAxTCBHQyAzICAgICB8IDIwMjVIMiAgfAp8ICvmm7/pm7fliKnnj6DljZXmipcgfCBIRVJJWk9OLTMwMSAxTCBIRVIyK0dFQSAzIOacn+aVsOaNruivu+WHuiB8IDIwMjVIMiAgfAp8IOWhlOaLieWmpeWNleaKlyB8ICAgICAgICAgICAgIHwgICAgICAgICB8CgrotYTmlpnmnaXmupDvvJrlhazlj7jmvJTnpLrmnZDmlpnvvIzlm73ph5Hor4HliLjnoJTnqbbmiYA=
所属报告:
百济神州(6160.HK)-港股公司研究报告:龙头Biopharma高举高打商业化和研发迎收获期-250805(31页).pdf
打包全文图表
相关数据
依沃西为全球首个在三期临床中头对头击败K药的新药,PFS强阳性(HR=0.51)
收藏
行业数据
2026-03-31
原图定位
查看详情
HARMONi-6试验主要终点:依沃西+化疗较对照臂PFS提升4.2个月(HR=0.60)
收藏
行业数据
2026-03-31
原图定位
查看详情
CARTITUDE-4 TME: Patients With Shorter PFS (≤18M) and Patients With More pLOT had a More Suppressive TME
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
收藏
行业数据
2026-03-11
原图定位
查看详情
CARTITUDE-4: PFS and OS in Patients With Standard-Risk Cytogenetics (As-Treated)
fCDnu4TliKsgfCAzMOS4quaciOaXoOi/m+WxleeUn+WtmOeOh++8iFBGUywgJe+8iSB8IDMw5Liq5pyI5oC755Sf5a2Y546H77yIT1MsICXvvIkgfAp8LS0tLS0tfC0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLXwtLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLXwKfCBDQVJUSVRVREUgLSA0IOagh+WHhumjjumZqSB8IDgwLjUgfCA4Ny4zIHwKfCBDQVJUSVRVREUgLSA0IOagh+WHhumjjumZqSArIGdhaW4vYW1wKDFxKSB8IDcxLjcgfCA4Ni4xIHwKCui1hOaWmeadpea6kO+8mlBBUlRJVFVERSAtIDQg56CU56m277yI5qCH5YeG6aOO6Zmp57uG6IOe6YGX5Lyg5a2m5oKj6ICFIEFzIC0gVHJlYXRlZCDliIbmnpDvvInmlbDmja4=
收藏
行业数据
2026-03-11
原图定位
查看详情
Figure 3: PFS (A) and OS (B)
fCDmjIfmoIcgICAgICAgfCAzNuS4quaciOeOhyB8IDk1JSDnva7kv6HljLrpl7QgfAp8LS0tLS0tLS0tLS0tfC0tLS0tLS0tLS18LS0tLS0tLS0tLS0tLS18CnwgUEZTICAgICAgICB8IDkzLjglICAgIHwgNjMuMuKAkzk5LjEgICAgfAp8IE9TICAgICAgICAgfCA5My44JSAgICB8IDYzLjLigJM5OS4xICAgIHwKCui1hOaWmeadpea6kO+8muWbvueJh+S4reKAnFJlc3VsdHPigJ3mnb/lnZflj4pGaWd1cmUgM++8iFBGUyAoQSkg5ZKMIE9TIChCKe+8ieWGheWuueOAgg==
收藏
行业数据
2026-03-11
原图定位
查看详情
T-DXd对HER2-lowBC的全人群PFS
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
收藏
行业数据
2025-11-24
原图定位
查看详情
Ivonescimab国内临床,PFS显著优于K药
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
收藏
行业数据
2025-10-24
原图定位
查看详情
izabren展现EGFRmNSCLC二线治疗历史最长PFS(单位:月)
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
收藏
行业数据
2025-09-16
原图定位
查看详情
Vepdegestrantvs氟维司群在HR+/HER2-BC(全人群)的PFS数据
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
收藏
行业数据
2025-08-08
原图定位
查看详情
R/RCLL最新PFS数据支持BGB-16673开展与匹妥布替尼的头对头试验
fCDpobnnm64gfCBCR0ItMTY2NzMgfCDljLnlronluIPmm7/lsLwgfAp8LS0tLS0tfC0tLS0tLS0tLS18LS0tLS0tLS0tLXwKfCBuICAgIHwgNjYgICAgICAgfCAxMTkgICAgICB8Cnwg5Lit5L2NUEZTLCDmnIggKDk1JSBDSSkgfCAyMi44ICgxNS42KSB8IDE0LjAgKDExLjItMTYuNikgfAp8IOS4reS9jemaj+iuv+aXtumXtCwg5pyIIHwgMTUuNiAgICAgIHwgMTkuNCAgICAgIHw=
收藏
行业数据
2025-08-07
原图定位
查看详情
无明确驱动基因NSCLC(无论PD-L1表达状态),依沃西PFS数据佳,SSGJ-707的ORR及安全性佳
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
收藏
行业数据
2025-07-17
原图定位
查看详情
Tarlatamab在PFS及癌症相关呼吸/咳嗽获益
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
收藏
行业数据
2025-07-15
原图定位
查看详情
戈利昔替尼与西达本胺的PFS曲线对比
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
收藏
行业数据
2025-06-23
原图定位
查看详情
外显子21(L858R)和外显子19缺失亚组PFS率对比
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
收藏
行业数据
2025-06-09
原图定位
查看详情
最新数据
全球全年龄段奶粉市场规模(亿美元)
收藏
行业数据
2026-07-30
原图定位
查看详情
全球酸奶及发酵乳制品市场规模(亿美元)
收藏
行业数据
2026-07-30
原图定位
查看详情
全球药用级益生菌市场规模(百万美元)
收藏
行业数据
2026-07-30
原图定位
查看详情
全球益生菌膳食补充剂市场规模及增速
收藏
行业数据
2026-07-30
原图定位
查看详情
全球拥有AKK专利菌株的核心企业
收藏
行业数据
2026-07-30
原图定位
查看详情
(2)销售发力错峰,Fix duration 发力与泽布替尼的生命周期管理相契合。泽布替尼+索托克拉针对一线 CLL 的 III 期临床试验 CELESTIAL-TNCLL(301)于 2023 月 11 月首例入组,2025 年 2 月完成全部入组,主要终点为 PFS,参考对照组维奈克拉+奥妥珠单抗在此前研究中的 PFS(CLL14 研究中 5 年 PFS 率 76 个月),我们预计数据成熟或仍需 4 年或以上。因此,泽布替尼+索托克拉方案获批一线 CLL 时泽布替尼已处于产品生命周期的中后期,联用方案的引入不挤占泽布替尼的市场,反而有望延长泽布替尼的生命周期。
行业数据
原图定位
当前图表所属:
百济神州(6160.HK)-港股公司研究报告:龙头Biopharma高举高打商业化和研发迎收获期-250805(31页).pdf
全球NHL发病人数持续增长,其中DLBCL、FL、CLL/SLL、MZL发病率较高
血液瘤分型复杂,NHL(包括CLL/SLL亚型)为核心市场之一
2025年和2026年关键早期催化剂:实体瘤管线迎来密集概念验证
2025年和2026年关键后期催化剂:血液瘤产品组合迎来加速兑现
下载图片或Excel,需升级至尊VIP会员或「预见者」VIP
立即去升级
客服
商务合作
小程序
服务号
回到顶部
折叠
微信扫码登录
微信扫码登录
双重福利,扫码领取!
关注公众号『三个皮匠报告』,免费领取报告
1.100+最新优质行业报告
2.每周免费精选报告分享
手机快捷登录
账号登录
记住密码
忘记密码?
验证即登录,未注册将自动创建账号
获取验证码
收不到验证码注意事项
登录代表您已阅读并同意
《三个皮匠服务条款》